When only the FMF patients with or without amyloidosis were considered, in patients who received anti-IL-1 therapy, the fibrinogen level, RDW, and NLR, as well as inflammatory parameters such as ESR and CRP, were higher in patients who had amyloidosis than those who had not. The gene discussed is IL1B; the disease is amyloidosis.